

**Contacts Media**

Amsterdam +31 20 721 4133  
Dublin +353 87 361 2380  
Milan +39 02 72 42 62 12  
Paris +33 1 70 48 24 45

Brussels +32 2 620 15 50  
Lisbon +351 210 600 614  
Oslo +47 41 69 59 10

**Contact Investor Relations**

+33 1 70 48 24 27

## HealthBeacon lists on Euronext Growth Dublin

- **€25 million raised – market capitalisation of €98.35 million**
- **First IPOready participant to list on Euronext markets**



**Dublin – 15 December 2021** – Euronext today congratulates HealthBeacon, an Irish digital therapeutics company that develops products for managing injectable medications for people in the home, on its listing on Euronext Growth Dublin (ticker code: HBCN). It is the first alumnus of Euronext's pre-IPO programme, IPOready, to list on Euronext markets.

The HealthBeacon injection care management system is the world's first FDA cleared smart sharps bin that tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools and AI-driven data analytics. The company is expecting approximately ten-fold increase in the number of patients using its systems from the end of 2021 to the end of 2023. HealthBeacon intends to use the proceeds from the placing to (i) scale its team to support growth across sales and marketing, customer support and operations, finance and product development (ii) invest in inventory and working capital to support product roll out and (iii) further develop its platform in respect of technology development, research and development and develop a pipeline of future products.

HealthBeacon was listed through the admission to trading of the 16,812,047 shares making up its equity and of 4,273,504 new shares issued in the placement phase, after full exercise of the extension option and over-allotment option.

The admission and issue price of HealthBeacon shares was set at €5.85 per share. Market capitalisation was €98.35 million on the day of listing. The Initial Public Offering (IPO) raised €25 million altogether.

Jim Joyce, CEO of HealthBeacon, said: *"HealthBeacon is delighted to be joining Euronext Growth in what is another important milestone on our journey towards connecting people to better health through digitally enabled solutions. The support from investors through this listing is transformative for the business, enabling us to scale to meet potential demand, as we aim to become the world's leading digital therapeutics platform for injectable medications. We are excited for our next phase of growth as a public company, backed by the potential of our target market and the proven ability for our product to meaningfully increase medical adherence for patients in a safe and sustainable way."*



**Caption:** Jim Joyce, CEO of HealthBeacon, Laurence Flavin, CFO of HealthBeacon, Kieran Daly, CTO and Co-Founder of HealthBeacon and Mary Harney, Non-Executive Director and Senior Independent Director of HealthBeacon, rang the bell during an opening bell ceremony this morning to celebrate the IPO of the company.

**CONTACTS MEDIA – [mediateam@euronext.com](mailto:mediateam@euronext.com)**

**Euronext**  
Shannon Sweeney (Dublin) +353 1 617 4249 [ssweeney@euronext.com](mailto:ssweeney@euronext.com)

**HealthBeacon**  
Cathal Barry +353 87 227 9281 [cathal.barry@drury.ie](mailto:cathal.barry@drury.ie)

**About HealthBeacon**

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops products for managing injectable medications for patients in the home. The HealthBeacon injection care management system tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools and AI driven data analytics. The Company operates in 17 markets across Europe, North America and the United Kingdom and employs more than 50 people.

**About Euronext**

Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 1,920 listed issuers and around €6.5 trillion in market capitalisation as of end September 2021, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.

For the latest news, go to [euronext.com](http://euronext.com) or follow us on Twitter ([twitter.com/euronext](https://twitter.com/euronext)) and LinkedIn ([linkedin.com/euronext](https://linkedin.com/euronext)).

**Disclaimer**

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided “as is”, without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All



proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at [www.euronext.com/terms-use](http://www.euronext.com/terms-use).

© 2021, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: [www.euronext.com/privacy-policy](http://www.euronext.com/privacy-policy). In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: [www.euronext.com/data\\_subjects\\_rights\\_request\\_information](http://www.euronext.com/data_subjects_rights_request_information). To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at [connect2.euronext.com/form/data-subjects-rights-request](http://connect2.euronext.com/form/data-subjects-rights-request) or email our Data Protection Officer at [dpo@euronext.com](mailto:dpo@euronext.com).

